NASDAQ
44.81USD
+1.54 (+3.56%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5.9B
P/E
—
EPS
—
Beta
2.26
52W range
12.882-49.2
Day range
43.62–45.31
Open
43.97
Prev close
43.27
Volume
898.4K
Avg volume
2.7M
Dividend
0.00
IPO
2016-11-15
https://www.benzinga.com/analyst-stock-ratings/initiation/26/08/61271176/this-definium-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday · 8/18/2026+0.80
https://www.fool.com/coverage/etfs/2026/07/08/which-healthcare-etf-is-the-better-buy-invesco-s-ibbq-or-state-street-s-xph/ · 7/8/2026-0.30
https://www.zacks.com/stock/news/2941580/definium-stock-soars-50-as-phase-iii-depression-study-meets-key-goals?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2941580 · 6/23/2026+1.00
https://www.proactiveinvestors.com/companies/news/1094279 · 6/22/2026+1.00
https://www.marketbeat.com/instant-alerts/definium-therapeutics-eyes-key-dt-120-depression-data-advances-anxiety-program-2026-05-22/ · 5/23/2026
https://seekingalpha.com/article/4893049-definium-therapeutics-inc-dftx-analyst-investor-day-transcript · 4/27/2026+0.00
https://www.fool.com/investing/2026/04/23/trump-backs-psychedelics-heres-1-company-investors/ · 4/24/2026+0.20
https://www.defenseworld.net/2026/03/21/definium-therapeutics-teases-3-key-dt-120-data-readouts-this-year-highlights-de-risked-phase-3-design.html · 3/21/2026+0.40
https://www.defenseworld.net/2026/02/14/definium-therapeutics-inc-nasdaqdftx-receives-average-rating-of-buy-from-brokerages.html · 2/14/2026+0.80
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
